Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancer

This study demonstrates that the novel EED inhibitor ORIC-944 is a more effective therapeutic strategy for incurable neuroendocrine prostate cancer than the PRC2 inhibitor tazemetostat, as it induces significant dose-dependent growth inhibition and apoptosis by simultaneously reactivating both PRC1 and PRC2 target genes.

The Gist

The Big Problem: The "Shape-Shifting" Cancer

Imagine the prostate as a factory that makes a specific type of product (normal cells). Sometimes, this factory gets damaged and starts making a dangerous product called Prostate Adenocarcinoma (PRAD). Doctors usually have good tools to stop this factory, like cutting off the fuel supply (hormone therapy).

However, in about 15% of cases, the cancer cells are like master shape-shifters. When they sense the fuel is cut off, they don't just die; they transform into a completely different, much more dangerous monster called Neuroendocrine Prostate Cancer (NEPC).

This new monster is a nightmare because:

1. It ignores the fuel-cutting treatments.
2. It is resistant to standard chemotherapy.
3. Currently, there is no cure for it. It is essentially an incurable disease.

The Villains: The "Silencers"

Inside these cancer cells, there are two evil managers working together called PRC1 and PRC2. Think of them as the "Silencers" of the cell.

• What they do: They take a marker (like a red stamp) and slap it onto the DNA of the cell's "good genes" (the genes that tell the cell to stop growing or to die).
• The result: The good genes are silenced. The cancer cells keep multiplying wildly and refuse to die.

In NEPC, these "Silencers" are working overtime. They are the reason the cancer is so aggressive.

The Old Weapon: Tazemetostat (The One-Tool Fix)

Scientists previously developed a drug called Tazemetostat.

• How it works: It targets only one of the two Silencers (PRC2).
• The Analogy: Imagine the cancer has two locks on its door. Tazemetostat is a key that only fits Lock A.
• The Problem: In the "shape-shifting" cancer (NEPC), Lock A isn't the only thing keeping the door shut. Even if you pick Lock A, the door stays closed because Lock B (PRC1) is still engaged.
• The Result: Tazemetostat works well on the original cancer (PRAD), but it fails completely against the shape-shifting NEPC.

The New Hero: ORIC-944 (The Master Key)

This paper introduces a new drug called ORIC-944.

• How it works: It targets EED. EED is a crucial part of the machinery that holds both Lock A and Lock B together.
• The Analogy: Instead of picking just one lock, ORIC-944 is like a master key that jams the entire locking mechanism. It disables both Silencers (PRC1 and PRC2) at the same time.

What Happened in the Lab?

The researchers tested both drugs on cancer cells in a petri dish. Here is what they found:

1. Growth Stop:

   • Tazemetostat: The cancer cells kept growing. The drug didn't work.
   • ORIC-944: The cancer cells stopped growing immediately. It worked on both the old cancer and the new, shape-shifting monster.

2. The "Self-Destruct" Button:

   • Tazemetostat: The cells were just sitting there, not dying.
   • ORIC-944: The drug didn't just stop growth; it hit the Self-Destruct button. It forced the cancer cells to commit suicide (a process called apoptosis).

3. Why did it work?
   The researchers looked at the genetic "instruction manual" inside the cells.

   • Both drugs turned on some "good" genes (like turning on the lights in a dark room).
   • However, ORIC-944 turned on a special set of genes that Tazemetostat missed. These special genes are like brakes and suicide signals.
   • Specifically, ORIC-944 reactivated genes called Metallothioneins. Think of these as the cell's internal security guards that say, "This is bad, we need to shut down." Because ORIC-944 targets both Silencers, it can unlock these specific guards, whereas Tazemetostat cannot.

The Bottom Line

This study suggests that to beat the incurable, shape-shifting Neuroendocrine Prostate Cancer, we need a Master Key, not a single-lock pick.

• Old Strategy: Try to stop the cancer by targeting one part of the machinery (failed).
• New Strategy: Target the central hub (EED) that controls the whole system. This turns the cancer's own "Silencers" against it, forcing the cancer cells to die.

Why this matters: This gives hope for a future treatment for a disease that currently has no cure. It suggests that drugs like ORIC-944 could be the key to unlocking a new era of treatment for aggressive prostate cancer.

Technical Summary

1. Problem Statement

Neuroendocrine Prostate Cancer (NEPC) is an aggressive, treatment-refractory malignancy that arises from the trans-differentiation of conventional prostate adenocarcinoma (PRAD) under the pressure of androgen deprivation therapy (ADT). NEPC is characterized by:

• Androgen independence (often AR-negative).
• Resistance to standard hormonal therapies and chemotherapy.
• A dismal prognosis with no curative therapeutic options currently available.

Epigenetic Dysregulation: NEPC exhibits over-activation of Polycomb Repressive Complexes 1 and 2 (PRC1 and PRC2). These complexes silence tumor suppressor genes via histone modifications:

• PRC2 catalyzes H3K27 trimethylation (H3K27me3) via the enzyme EZH2.
• PRC1 catalyzes H2AK119 monoubiquitination (H2AK119ub).

The Therapeutic Gap: While EZH2 inhibitors (e.g., tazemetostat) are approved for sarcomas and lymphomas and show efficacy in PRAD, they have failed to inhibit the growth of NEPC cells. This failure persists despite the high expression of EZH2 and its binding partner EED (Embryonic Ectoderm Development) in NEPC. The authors hypothesize that targeting EED, a core component required for the function of both PRC1 and PRC2, may overcome the limitations of EZH2-specific inhibition.

2. Methodology

The study employed a multi-modal approach comparing a traditional EZH2 inhibitor (tazemetostat) against a novel EED inhibitor (ORIC-944) across human and murine cell models.

• Cell Models:
  • PRAD: LNCaP (human).
  • NEPC: KUCaP13 (human), ST4787 (murine), and T23 (murine adenocarcinoma control).
  • Conditions: Experiments were conducted in both normoxia (21% O₂) and hypoxia (2% O₂), the latter being a known driver of treatment resistance.
• Pharmacological Agents:
  • Tazemetostat: Selective EZH2 inhibitor.
  • ORIC-944: Selective EED inhibitor.
  • Valemetostat: Double EZH1/EZH2 inhibitor (used as a control to rule out EZH1/2 dual inhibition as the mechanism).
  • Controls: Carboplatin, Olaparib, and DMSO.
• Assays:
  • Viability: CellTiter-Blue (normoxia) and Trypan Blue/automated counting (hypoxia) to determine IC₅₀ values.
  • Apoptosis: Flow cytometry using Annexin V/Propidium Iodide (PI) staining.
  • Epigenetic Validation: ELISA and Western Blotting to quantify global H3K27me3 and H2AK119ub levels.
  • Transcriptomics: Bulk RNA-Sequencing (RNA-Seq) followed by differential expression analysis (DESeq2) and Gene Set Enrichment Analysis (GSEA).
  • Comparative Analysis: Identification of "Preferentially ORIC-944 Dependent genes" (PODs) by comparing ORIC-944 vs. Tazemetostat treatment.

3. Key Contributions

1. Demonstration of EED Inhibitor Efficacy in NEPC: The study provides the first evidence that pharmacological inhibition of EED (via ORIC-944) effectively induces growth inhibition and apoptosis in NEPC models, whereas EZH2 inhibition (tazemetostat) does not.
2. Mechanistic Differentiation: The authors elucidate that while both drugs reduce H3K27me3, only EED inhibition reactivates a specific subset of PRC1-targeted pro-apoptotic and growth-suppressive genes.
3. Identification of PODs: The study defines a specific gene signature (PODs) that distinguishes the therapeutic mechanism of EED inhibition from EZH2 inhibition, highlighting the unique ability of EED targeting to unlock PRC1-mediated tumor suppression.
4. Hypoxia Resilience: The efficacy of ORIC-944 was maintained under hypoxic conditions, a critical finding given the hypoxic microenvironment of advanced tumors.

4. Key Results

A. Differential Growth Inhibition

• Tazemetostat: Induced dose-dependent growth inhibition in PRAD (LNCaP) cells (IC₅₀ ≈ 0.05 µM) but was ineffective in NEPC cells (KUCaP13, ST4787), where no IC₅₀ could be calculated.
• ORIC-944: Induced potent, dose-dependent growth inhibition in both PRAD and NEPC cells.
  • IC₅₀ values in NEPC ranged from 0.13 µM to 2.84 µM.
  • In ST4787 cells, ORIC-944 was as effective as, or more effective than, clinically used agents like Carboplatin and Olaparib.
  • Efficacy was preserved under hypoxia (2% O₂).
• Control: Valemetostat (EZH1/2 inhibitor) failed to inhibit ST4787 growth, confirming that the effect of ORIC-944 is not due to dual EZH1/2 inhibition but rather EED targeting.

B. Induction of Apoptosis

• Flow cytometry revealed that ORIC-944 significantly induced apoptosis in NEPC cells (ST4787) after 3 days of treatment.
• Tazemetostat failed to induce significant apoptosis or cell death in NEPC cells, despite reducing H3K27me3 levels.

C. Epigenetic and Transcriptomic Mechanisms

• Histone Marks: Both drugs successfully reduced global H3K27me3 levels, confirming PRC2 inhibition.
• Shared Pathways: Both compounds reactivated neural differentiation genes and WNT pathway modulators (typical of Polycomb target reactivation).
• Unique Pathways (PODs):
  • RNA-Seq identified 10 PODs in KUCaP13 and 362 PODs in ST4787 that were significantly upregulated by ORIC-944 but not by tazemetostat.
  • Gene Ontology: PODs were enriched for "negative regulation of growth," "pattern specification," and "regionalization."
  • PRC1 Specificity: Crucially, PODs were significantly enriched for selective PRC1 targets.
  • Specific Genes:
    • Metallothioneins (MT1G, MT1H, MT1F): Known tumor suppressors that promote apoptosis and inhibit cell cycle progression. Their reactivation is linked to the apoptotic phenotype.
    • WNT Modulators & Bcl11b: Involved in developmental pathways and apoptosis.

5. Significance and Conclusion

The study concludes that EED inhibition is a superior therapeutic strategy for NEPC compared to EZH2 inhibition.

• Mechanistic Insight: The failure of tazemetostat in NEPC is likely due to the inability to inhibit PRC1-dependent pathways. NEPC cells are AR-indifferent, rendering the non-canonical AR-coactivator function of EZH2 (targeted by tazemetostat in PRAD) irrelevant. However, EED is essential for the structural integrity and function of both PRC1 and PRC2.
• Therapeutic Implication: By targeting EED, ORIC-944 simultaneously disrupts PRC1 and PRC2, leading to the reactivation of a broader spectrum of tumor suppressors, specifically PRC1 targets like metallothioneins, which drive apoptosis in NEPC.
• Clinical Relevance: These findings support the advancement of EED inhibitors (like ORIC-944) into clinical trials for aggressive variant prostate cancer, offering a potential solution to the unmet need for treating incurable NEPC.

Future Directions: The authors plan to validate these findings in in vivo models and explore combination therapies based on the identified transcriptomic signatures.